Just launched - feedback most welcome!
Send feedback

COVID-19 Evidence Alerts
from McMaster PLUSTM

Current best evidence for clinical care (more info)

Back to homepage

Treatment Cortegiani A, Ippolito M, Greco M, et al. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. Pulmonology. 2020 Jul 20. pii: S2531-0437(20)30153-7. doi: 10.1016/j.pulmoe.2020.07.003.
Abstract

BACKGROUND: Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety.

METHODS: MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis until 20th June 2020.

RESULTS: We identified 3 indirect pre-clinical studies and 28 clinical studies including 5776 patients with COVID-19 (13 with a comparison group, 15 single-arm). To date, no randomized trials have been published. We retrieved no studies at low risk of bias. Forty-five ongoing studies were retrieved from trial registries.

CONCLUSIONS: There is insufficient evidence regarding the clinical efficacy and safety of tocilizumab in patients with COVID-19. Its use should be considered experimental, requiring ethical approval and clinical trial oversight.

Ratings
Discipline / Specialty Area Score
Hospital Doctor/Hospitalists
Coming soon...
Infectious Disease
Coming soon...
Intensivist/Critical Care
Coming soon...
Internal Medicine and its subspecialties
Coming soon...
Respirology/Pulmonology
Coming soon...